This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: University College Cardiff Consultants Limited. Active years: 2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022
Title: Stefania Fasano: Innovator in Neuroprotective Peptides
Introduction
Stefania Fasano is a prominent inventor based in Milan, Italy. She has made significant contributions to the field of neuroprotective peptides, focusing on their potential applications in treating neurodegenerative and neuropsychiatric disorders. Her innovative work has garnered attention in the scientific community.
Latest Patents
Stefania Fasano holds a patent for a neuroprotective peptide that acts as an inhibitor of MAPK3 (ERK1 MAP kinase). This patent discloses polypeptides that stimulate the global ERK signaling pathway in the brain. The invention includes related polynucleotides, vectors, host cells, and pharmaceutical compositions that inhibit MAPK3, thereby stimulating the global ERK signaling pathway. Additionally, the patent outlines the use of these inhibitors or stimulators in treating cognitive impairment and various neurodegenerative disorders.
Career Highlights
Stefania Fasano's career is marked by her dedication to advancing the understanding of neuroprotective agents. Her research has implications for enhancing cognitive function and providing therapeutic options for individuals suffering from neurodegenerative diseases.
Collaborations
Stefania has collaborated with notable colleagues, including Riccardo Brambilla and Marzia Indrigo, to further her research and development efforts in this critical area of study.
Conclusion
Stefania Fasano's innovative work in neuroprotective peptides represents a significant advancement in the field of neuroscience. Her contributions have the potential to improve the lives of many individuals affected by cognitive impairments and neurodegenerative disorders.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
